MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Total Non-current Assets
All assets not expected to be converted to cash within one year.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Total Non-current Assets · Q3 FY2026 · quarter ended Sep 2026
Total non-current assets rises 205.2% from a year ago
Total non-current assets stood at $7.86M at the end of Q3 FY2026, up 205.2% from a year earlier and down 2.4% from the prior quarter. Over 3 fiscal years it compounded at +59.8% a year.
Context
- Total non-current assets amounted to 1.6% of total assets at the end of Q3 FY2026, up 0.9 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +205.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 3.61M USD
- Year-over-year change
- +188.6%
- 3-year CAGR
- +59.8%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.61M | +188.6% |
| FY2024 | 2024-12-31 | 1.25M | +74.7% |
| FY2023 | 2023-12-31 | 715K | -19.1% |
| FY2022 | 2022-12-31 | 884K | — |
Total Non-current Assets vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +205.2% is the 4th highest of 8, against a peer median of +96.9%.
- Total non-current assets amounts to 1.6% of total assets for MBX, versus a peer median of 14.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €840.23M EUR | +513.4% | +5.2% | 34.6% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $282.25M USD | — | — | 23.3% |
| Mar 2026 | $200.7M USD | +1149.4% | +178.2% | 74.7% | |
| Mar 2026 | $140.33M USD | -7.7% | -3.2% | 35.8% | |
| Sep 2026 | $23.77M USD | +96.9% | -22.2% | 5.4% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $7.86M USD | +205.2% | +59.8% | 1.6% |
| Jun 2026 | $4.33M USD | +419.7% | -55.5% | 0.8% | |
| Mar 2026 | $954K USD | -52.3% | -50.3% | 0.3% | |
| Mar 2026 | $67K USD | -99.4% | -64.3% | 0.1% | |
| Peer median (excluding MBX) | — | +96.9% | -22.2% | 14.3% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.